jeudi 15 novembre 2018

Onco Actu du 15 novembre 2018

3.1.1 Prévention - Tabac - e-cigs

Being around vapers does not undermine desire to quit smoking [BMC Medicine]

4. Dépistage, diagnostic et pronostic

With free brain tumor screening, the road to early detection may be filled with potholes [HealthNewsReview]

4.12 Biopsies liquides

Methylation-Based Cancer Early Detection Method Shows Promise in Preliminary Studies [Genome Web]

4.7 Dép., diag. & prono. - Col de l'utérus

Capita’s cancer screening blunder hits 50,000 NHS patients [The Guardian]

Thousands caught up in 'appalling' cervical screening blunder [BBC News]

5.1 Traitements - Pré-clinique

Bromopyruvate Revealed [In the Pipeline]

5.12 Immunothérapies

Side Effects From Certain Immunotherapies May Be Higher Than Initially Reported [ASCO]

Researchers apply leap of faith to preliminary study of fecal transplant for immunotherapy-induced colitis [HealthNewsReview]

Lymphoma [Nature Outlook]

5.12.1 Immunothérapies - partenariats

Celgene expands Dragonfly NK cells pact to the tune of $50M [FierceBiotech]

Celgene Doubles Down on Dragonfly, Pays $50M to Expand Cancer Pact [Xconomy]

5.12.5 Immunothérapies - Pharma

Merck's Keytruda picks up first-in-class survival win in esophageal cancer [FiercePharma]

Merck’s KEYTRUDA® (pembrolizumab) Significantly Improved Overall Survival (OS) Compared to Chemotherapy in Patients with Advanced Esophageal or Esophagogastric Junction Carcinoma Whose Tumors Express PD-L1 (CPS ≥10) [Merck]

Eluded by clear success in esophageal carcinoma, Merck touts subgroup OS win for Keytruda [EndPoints]

Merck drug Keytruda succeeds in late-stage esophageal cancer trial [Reuters]

5.3 Traitements - FDA, EMA, NICE...

What’s coming? Pazdur, Marks and Woodcock discuss FDA changes [EndPoints]

5.3.4 Traitements - AMM (FDA, EMA,...)

Exelixis’ Partner Ipsen Receives European Commission Approval for CABOMETYX® (cabozantinib) Tablets for the Treatment of Hepatocellular Carcinoma in Adults Previously Treated with Sorafenib [Exelixis]

5.9.4 ENA

Combination of two immunotherapies shows activity in non-small cell lung cancer patients [ECCO]

Drug combination makes cancer disappear in mice with neuroblastoma ‘significant’ findings suggest potential for effective, non-toxic treatment for this aggressive childhood cancer [ECCO]

Difficult-to-treat bowel cancers respond in first study of new drug combination [ECCO]

A Spark Of Good News For Precision Oncology In Breast Cancer [Forbes]

6.1 Observation

From heart disease to cancer: New study tracks shift of county death rates [Stanford Medicine]

6.10 Politiques

Brexit: what the draft deal means for science [Nature]

6.7 DMP, Big Data & applis

Hospitals Lagging in Using Discrete Genomics Data for Clinical Decision Support [Genome Web]

Google 'betrays patient trust' with DeepMind Health move [The Guardian]

At 24, Two Entrepreneurs Took On Cancer. At 32, They’re Worth Hundreds Of Millions [Forbes]

6.7.1 IA/bioinformatique

Did IBM overhype Watson Health's AI promise? [Computer World]

6.9 Controverses

Jury clears J&J of liability in California talc cancer case [Reuters]